Board Member
GoodRx Holdings, Inc. (GDRX)Equibles does not estimate personal net worth.
Get an email with a short summary when GoodRx Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get GDRX alertsWendy Barnes is recorded as Board Member at GoodRx Holdings, Inc. (GDRX) since April 1, 2026 and CEO at GoodRx Holdings, Inc. (GDRX). The newest filing on record that lists Wendy Barnes as CEO and Board Member at GoodRx Holdings, Inc. (GDRX) is dated April 29, 2026. GoodRx Holdings, Inc. reported in an 8-K filed April 3, 2026 that Wendy Barnes was appointed Class III director, effective April 1, 2026. GoodRx Holdings, Inc. reported in an 8-K filed April 3, 2026 that Wendy Barnes resigned as director, effective April 1, 2026. GoodRx Holdings, Inc. reported in an 8-K filed December 16, 2024 that Wendy Barnes was appointed Class I director, effective January 1, 2025. Equibles holds 4 filed executive changes naming Wendy Barnes; each is listed under recent activity with its source filing. The proxy statement of GoodRx Holdings, Inc. reports total compensation of $23,367,483 for Wendy Barnes in fiscal 2025, including a base salary of $825,000. Wendy Barnes has spoken on 7 earnings calls across 1 company, most recently for GoodRx Holdings, Inc. on August 6, 2026. GoodRx Holdings, Inc. is classified in the Health Information Services industry within the Healthcare sector. Other leadership on record at GoodRx Holdings, Inc. includes Scott Wagner (CEO, Chairman and Board Member), Trevor Bezdek (Chairman), Christopher A. McGinnis (CFO) and 7 others.
“On April 1, 2026, Ms. Barnes, who served as a Class I director, tendered her resignation as a director, effective upon her election by the Board as a Class III director.”
“On April 1, 2026, Ms. Barnes, who served as a Class I director, tendered her resignation as a director, effective upon her election by the Board as a Class III director.”
“The second quarter was a strong quarter for GoodRx. We exceeded our revenue expectations, maintained disciplined profitability, and saw meaningful consumer engagement across the platform.”
“We delivered a strong first quarter with performance driven by continued momentum across our strategic growth priorities. We are seeing strength in revenue, disciplined execution on profitability, and healthy engagement across the platform.”
“The fourth quarter marked a strong finish to the year and reflected discipline execution across our strategic priorities. We expanded direct-to-consumer affordability programs with pharmaceutical manufacturers, scaled differentiated subscription offerings, and deepened relationships with retail pharmacies.”
“Q3 was a strong quarter of focused execution and measurable progress across each of our key strategic priorities.”
“Our business continues to deliver strong adjusted EBITDA margins, and our team is executing on a number of fronts that we believe will help deliver long-term growth opportunities.”
2026-04-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
2025-01-01–2026-04-01
Health Information Services · Healthcare
CEO, Board Member
2025-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GoodRx Holdings, Inc. (GDRX) | Chief Executive Officer & President | $825,000 | $23,367,483 |
